Related references
Note: Only part of the references are listed.Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
P. Garcia-Alfonso et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2022)
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines
Carin A. T. C. Lunenburg et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2020)
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Sona Vodenkova et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update
Pan Xie et al.
CELLULAR ONCOLOGY (2020)
Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants
Carin A. T. C. Lunenburg et al.
GENES (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Ursula Amstutz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks et al.
LANCET ONCOLOGY (2015)
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel et al.
MOLECULAR CANCER THERAPEUTICS (2006)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Share Paper
